Ocular Therapeutix CSO reports small 3,469-share Form 4 sale

Q: What insider transaction did OCUL report in this Form 4?

The Form 4 reports that Chief Scientific Officer Jeffrey S. Heier sold 3,469 shares of Ocular Therapeutix common stock on 11/24/2025 at a weighted average price of $12.04 per share.

Q: Why did Jeffrey S. Heier sell OCUL shares on November 24, 2025?

The filing explains the 3,469 shares were sold under a durable automatic sale instruction to effect a sell-to-cover election for tax withholding obligations related to restricted stock units that vested on November 22, 2025 .

Q: What was the trading price range for the OCUL shares sold?

The weighted average sale price was $12.04 , with individual trades executed at prices ranging from $11.80 to $12.3207 , inclusive.

Q: What is the role of the reporting person in Ocular Therapeutix (OCUL)?

The reporting person, Jeffrey S. Heier , is identified as an officer of Ocular Therapeutix, serving as its Chief Scientific Officer .

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Ocular Therapeutix, Inc. (OCUL) reported an insider transaction by its Chief Scientific Officer, Jeffrey S. Heier. On 11/24/2025, he sold 3,469 shares of common stock at a weighted average price of $12.04 per share, through multiple trades between $11.80 and $12.3207. The filing states this was an automatic sale under a durable instruction adopted on April 9, 2024, to cover tax withholding obligations related to restricted stock units that vested on November 22, 2025, and that the trades were not discretionary. Following this transaction, Heier beneficially owned 245,940 shares of Ocular Therapeutix common stock in direct ownership.

Insights

Routine, pre-planned insider sale to cover RSU taxes; neutral impact.

This filing shows Ocular Therapeutix’s Chief Scientific Officer, Jeffrey S. Heier, sold 3,469 shares of common stock on 11/24/2025 at a weighted average price of $12.04. The sale is described as being executed under a durable automatic sale instruction adopted on April 9, 2024, tied to the vesting of restricted stock units on November 22, 2025.

The disclosure states the purpose was to satisfy tax withholding obligations from RSU vesting and that the trades were not discretionary. After the sale, Heier still held 245,940 shares directly, indicating the transaction is relatively small compared with his remaining position. Because it is a pre-arranged, tax-related sale, it reads as an administrative equity-compensation event rather than a change in company outlook.

Insider Trade Summary

Net Seller: 3,469 shares ($41,767)

Net Sell 1 txn

Insider Heier Jeffrey S.

Role Chief Scientific Officer

Sold 3,469 shs ($42K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,469	$12.04	$42K

Holdings After Transaction: Common Stock — 245,940 shares (Direct)

Footnotes (1)

Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.3207, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

11/26/2025 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heier Jeffrey S.

(Last)

(First)

(Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD

01730

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/24/2025		S⁽¹⁾		3,469⁽¹⁾	D	$12.04⁽²⁾	245,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.3207, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Todd Anderman, Attorney-in-Fact for Jeffrey S. Heier	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did OCUL report in this Form 4?

The Form 4 reports that Chief Scientific Officer Jeffrey S. Heier sold 3,469 shares of Ocular Therapeutix common stock on 11/24/2025 at a weighted average price of $12.04 per share.

Why did Jeffrey S. Heier sell OCUL shares on November 24, 2025?

The filing explains the 3,469 shares were sold under a durable automatic sale instruction to effect a sell-to-cover election for tax withholding obligations related to restricted stock units that vested on November 22, 2025.

Was the OCUL insider sale by Jeffrey S. Heier a discretionary trade?

No. The filing states the sales were made under a pre-established automatic instruction adopted on April 9, 2024 and that they do not represent a discretionary trade by the reporting person.

How many OCUL shares does Jeffrey S. Heier own after this transaction?

After the reported sale, Jeffrey S. Heier beneficially owned 245,940 shares of Ocular Therapeutix common stock in direct ownership.

What was the trading price range for the OCUL shares sold?

The weighted average sale price was $12.04, with individual trades executed at prices ranging from $11.80 to $12.3207, inclusive.

What is the role of the reporting person in Ocular Therapeutix (OCUL)?

The reporting person, Jeffrey S. Heier, is identified as an officer of Ocular Therapeutix, serving as its Chief Scientific Officer.